Dr. Haffty has published work which evaluates cancer biomarkers by staining TMA (Tissue Micro Array) slides to predict responses to various therapy and clinical outcomes.
Select publications include:
Eladoumikdachi F, Chakraborty MA, Ohri N, Kowzun M, Kumar S, Toppmeyer D, Haffty BG. Impact of Preoperative Radiation Boost on Oncotype DX® Result in a Phase II Clinical Trial. Ann Surg Oncol. 2025 Jul 9. doi: 10.1245/s10434-025-17799-4. Epub ahead of print. PMID: 40634811.
Yehia ZA, Sherwani Z, Chakraborty M, Ohri N, Grann A, Eladoumikdachi F, Kowzun M, Kumar S, Potdevin L, Blackwood M, Toppmeyer D, Haffty BG. First Results of the Primary Outcome of a Phase 2 Prospective Clinical Trial to Assess the Feasibility of Preoperative Radiation Boost in Patients With Breast Cancer. Int J Radiat Oncol Biol Phys. 2025 Feb 1;121(2):333-340. doi: 10.1016/j.ijrobp.2024.08.043. Epub 2024 Sep 4. PMID: 39241809.
Kim J, Fahmy V, Haffty BG. Radiation therapy for triple-negative breast cancer: from molecular insights to clinical perspectives. Expert Rev Anticancer Ther. 2024 May;24(5):211-217. doi: 10.1080/14737140.2024.2333320. Epub 2024 Mar 21. PMID: 38502143.
Kumar R, Krupa K, Yehia ZA, Kumar S, Potdevin L, Eladoumikdachi F, Kowzun MJ, Goyal S, Ohri N, Toppmeyer D, Haffty BG. Long-Term Clinical and Cosmetic Outcomes of Once-Daily Accelerated Partial Breast Irradiation in Early Breast Cancer. Adv Radiat Oncol. 2023 Jul 23;9(1):101324. doi: 10.1016/j.adro.2023.101324. PMID: 38260231; PMCID: PMC10801640.
Jhawar SR, Wang SJ, Thandoni A, Bommareddy PK, Newman JH, Marzo AL, Kuzel TM, Gupta V, Reiser J, Daniels P, Schiff D, Mitchell D, LeBoeuf NR, Simmons C, Goyal S, Lasfar A, Guevara-Patino JA, Haffty BG, Kaufman HL, Silk AW, Zloza A, Giurini EF. Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer. J Immunother Cancer. 2023 Jul;11(7):e006780. doi: 10.1136/jitc-2023-006780. Erratum in: J Immunother Cancer. 2024 Jan 31;12(1):e006780corr1. doi: 10.1136/jitc-2023-006780corr1. PMID: 37433716; PMCID: PMC10347455.
Kim J, Haffty BG. Genetic Factors in the Screening and Imaging for Breast Cancer. Korean J Radiol. 2023 May;24(5):378-383. doi: 10.3348/kjr.2023.0012. Epub 2023 Mar 30. PMID: 37056158; PMCID: PMC10157325.
Liu J, Zhang C, Zhang T, Chang CY, Wang J, Bazile L, Zhang L, Haffty BG, Hu W, Feng Z. Metabolic enzyme LDHA activates Rac1 GTPase as a noncanonical mechanism to promote cancer. Nat Metab. 2022 Dec;4(12):1830-1846. doi: 10.1038/s42255-022-00708-4. Epub 2022 Dec 19. PMID: 36536137; PMCID: PMC9794117.
Modi C, Dragun AE, Henson CF, Jain S, Ahlawat S, Eastwick G, Kubicek GJ, Mezera M, Mulvihill DJ, Perri J, Juneja B, Khullar K, Ennis RD, Haffty BG. A Statewide Multi-Institutional Study of Asymptomatic Pretreatment Testing of Radiation Therapy Patients for SARS-CoV-2 in a High-Incidence Region of the United States. Adv Radiat Oncol. 2021 Jul-Aug;6(4):100704. doi: 10.1016/j.adro.2021.100704. Epub 2021 Apr 20. PMID: 33898867; PMCID: PMC8055497.
Gupta A, Jhawar SR, Sayan M, Yehia ZA, Haffty BG, Yu JB, Wang SY. Cost-Effectiveness of Adjuvant Treatment for Ductal Carcinoma In Situ. J Clin Oncol. 2021 Jul 20;39(21):2386-2396. doi: 10.1200/JCO.21.00831. Epub 2021 May 21. PMID: 34019456; PMCID: PMC10166354.
Sayan M, Yehia ZA, Ohri N, Haffty BG. Hypofractionated Postmastectomy Radiation Therapy. Adv Radiat Oncol. 2020 Nov 21;6(1):100618. doi: 10.1016/j.adro.2020.11.003. PMID: 33490735; PMCID: PMC7809517.
Jan I, Chen K, Sayan M, Uprety P, Laumbach RJ, Ennis RD, Haffty BG. Prevalence of Surface Contamination With SARS-CoV-2 in a Radiation Oncology Clinic. JAMA Oncol. 2020 Oct 1;6(10):1632-1634. doi: 10.1001/jamaoncol.2020.3552. PMID: 32852509; PMCID: PMC7453342.
Haffty BG, Euhus DM, Pierce LJ. Genetic Factors in the Locoregional Management of Breast Cancer. J Clin Oncol. 2020 Jul 10;38(20):2220-2229. doi: 10.1200/JCO.19.02859. Epub 2020 May 22. PMID: 32442063.
Ohri N, Haffty BG. The evolution of adjuvant radiation therapy for early-stage and locally advanced breast cancer. Breast J. 2020 Jan;26(1):59-64. doi: 10.1111/tbj.13715. Epub 2019 Dec 19. PMID: 31854499.
Gupta A, Khan AJ, Yegya-Raman N, Sayan M, Ahlawat S, Ohri N, Goyal S, Moore DF, Eladoumikdachi F, Toppmeyer D, Haffty BG. 5-Year Results of a Prospective Phase 2 Trial Evaluating 3-Week Hypofractionated Whole Breast Radiation Therapy Inclusive of a Sequential Boost. Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):267-274. doi: 10.1016/j.ijrobp.2019.05.063. Epub 2019 Jun 5. PMID: 31175905; PMCID: PMC9710864.
Khan AJ, LaCava S, Mehta M, Schiff D, Thandoni A, Jhawar S, Danish S, Haffty BG, Chen S. The glutamate release inhibitor riluzole increases DNA damage and enhances cytotoxicity in human glioma cells, in vitro and in vivo. Oncotarget. 2019 Apr 19;10(29):2824-2834. doi: 10.18632/oncotarget.26854. PMID: 31073373; PMCID: PMC6497458.
Gupta A, Ohri N, Haffty BG. Hypofractionated whole breast irradiation is cost-effective-but is that enough to change practice? Transl Cancer Res. 2018 Apr;7(Suppl 4):S469-S472. doi: 10.21037/tcr.2018.03.20. PMID: 30123739; PMCID: PMC6097715.
Khan AJ, Misenko SM, Thandoni A, Schiff D, Jhawar SR, Bunting SF, Haffty BG. VX-984 is a selective inhibitor of non-homologous end joining, with possible preferential activity in transformed cells. Oncotarget. 2018 May 25;9(40):25833-25841. doi: 10.18632/oncotarget.25383. PMID: 29899825; PMCID: PMC5995231.
Liu J, Zhang C, Zhao Y, Yue X, Wu H, Huang S, Chen J, Tomsky K, Xie H, Khella CA, Gatza ML, Xia D, Gao J, White E, Haffty BG, Hu W, Feng Z. Parkin targets HIF-1α for ubiquitination and degradation to inhibit breast tumor progression. Nat Commun. 2017 Nov 28;8(1):1823. doi: 10.1038/s41467-017-01947-w. PMID: 29180628; PMCID: PMC5703960.
Droz-Rosario R, Lu H, Liu J, Liu NA, Ganesan S, Xia B, Haffty BG, Shen Z. Roles of BCCIP deficiency in mammary tumorigenesis. Breast Cancer Res. 2017 Oct 18;19(1):115. doi: 10.1186/s13058-017-0907-5. PMID: 29047390; PMCID: PMC5648485.
Stein MN, Bertino JR, Kaufman HL, Mayer T, Moss R, Silk A, Chan N, Malhotra J, Rodriguez L, Aisner J, Aiken RD, Haffty BG, DiPaola RS, Saunders T, Zloza A, Damare S, Beckett Y, Yu B, Najmi S, Gabel C, Dickerson S, Zheng L, El-Deiry WS, Allen JE, Stogniew M, Oster W, Mehnert JM. First-in-Human Clinical Trial of Oral ONC201 in Patients with Refractory Solid Tumors. Clin Cancer Res. 2017 Aug 1;23(15):4163-4169. doi: 10.1158/1078-0432.CCR-16-2658. Epub 2017 Mar 22. PMID: 28331050; PMCID: PMC7595575.
Zhang C, Liu J, Huang G, Zhao Y, Yue X, Wu H, Li J, Zhu J, Shen Z, Haffty BG, Hu W, Feng Z. Cullin3-KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression. Genes Dev. 2016 Sep 1;30(17):1956-70. doi: 10.1101/gad.283283.116. PMID: 27664236
Zhang C, Liu J, Zhao Y, Yue X, Zhu Y, Wang X, Wu H, Blanco F, Li S, Bhanot G, Haffty BG, Hu W, Feng Z. Glutaminase 2 is a novel negative regulator of small GTPase Rac1 and mediates p53 function in suppressing metastasis. Elife. 2016 Jan 11;5:e10727. doi: 10.7554/eLife.10727. PMID: 26751560
Mehta M, Khan A, Danish S, Haffty BG, Sabaawy HE. Radiosensitization of Primary Human Glioblastoma Stem-like Cells with Low-Dose AKT Inhibition. Mol Cancer Ther. 2015 May;14(5):1171-80. doi: 10.1158/1535-7163.MCT-14-0708.
Wall BA, Yu LJ, Khan A, Haffty B, Goydos JS, Chen S. Riluzole is a radio-sensitizing agent in an in vivo model of brain metastasis derived from GRM1 expressing human melanoma cells. Pigment Cell Melanoma Res. 2015 Jan;28(1):105-9. doi: 10.1111/pcmr.12327.
Wu H, Schiff DS, Lin Y, Neboori HJ, Goyal S, Feng Z, Haffty BG. Ionizing radiation sensitizes breast cancer cells to Bcl-2 inhibitor, ABT-737, through regulating Mcl-1. Radiat Res. 2014 Dec;182(6):618-25. doi: 10.1667/RR13856.1. PMID: 25409124
Li X, Li L, Moran MS, Jiang L, Kong X, Zhang H, Zhang X, Haffty BG, Yang Q. Prognostic significance of calcium-sensing receptor in breast cancer. Tumour Biol. 2014 Jun;35(6):5709-15. doi: 10.1007/s13277-014-1756-9. Epub 2014 Mar 1. PMID: 24584713
Li X, Yang Q, Yu H, Wu L, Zhao Y, Zhang C, Yue X, Liu Z, Wu H, Haffty BG, Feng Z, Hu W. LIF promotes tumorigenesis and metastasis of breast cancer through the AKT-mTOR pathway. Oncotarget. 2014 Feb 15;5(3):788-801. PMID: 24553191
Wall BA, Wangari-Talbot J, Shin SS, Schiff D, Sierra J, Yu LJ, Khan A, Haffty B, Goydos JS, Chen S. Disruption of GRM1-mediated signalling using riluzole results in DNA damage in melanoma cells. Pigment Cell Melanoma Res. 2014 Mar;27(2):263-74. doi: 10.1111/pcmr.12207. Epub 2014 Jan 22. PMID: 24330389
Schonewolf CA, Mehta M, Schiff D, Wu H, Haffty BG, Karantza V, Jabbour SK. Autophagy inhibition by chloroquine sensitizes HT-29 colorectal cancer cells to concurrent chemoradiation. World J Gastrointest Oncol. 2014 Mar 15;6(3):74-82. doi: 10.4251/wjgo.v6.i3.74.
Li Y, Moran MS, Huo Q, Yang Q, Haffty BG. Post-mastectomy radiotherapy for breast cancer patients with t1-t2 and 1-3 positive lymph nodes: a meta-analysis. PLoS One. 2013 Dec 3;8(12):e81765. doi: 10.1371/journal.pone.0081765. eCollection 2013. PMID: 24312582 [PubMed - indexed for MEDLINE]
Khan AJ, Parikh RR, Neboori HJ, Goyal S, Haffty BG, Moran MS. The relative benefits of tamoxifen in older women with T1 early-stage breast cancer treated with breast-conserving surgery and radiation therapy. Breast J. 2013 Sep-Oct;19(5):490-5. doi: 10.1111/tbj.12150. Epub 2013 Jun 26. PMID: 23800027 [PubMed - indexed for MEDLINE]
Jones T, Neboori HJ, Wu H et. al.; Are Breast Cancer Subtypes Prognostic for Nodal Involvement and Associated With Clinical-Pathologic Features at Presentation in Early-Stage Breast Cancer?; Annals of Surgical Oncology. PMID: 23661183; Published September, 2013.
Danish HH, Goyal S, Taunk NK, Wu H, Moran MS, Haffty BG. Interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) as a prognostic marker for local control in T1-2 N0 breast cancer treated with breast-conserving surgery and radiation therapy (BCS + RT). Breast J. 2013 May-Jun;19(3):231-9. doi: 10.1111/tbj.12097. Epub 2013 Mar 26. PMID: 23528130 [PubMed - indexed for MEDLINE]
Li X, Xu B, Moran MS, Zhao Y, Su P, Haffty BG, Shao C, Yang Q. 53BP1 functions as a tumor suppressor in breast cancer via the inhibition of NF-κB through miR-146a. Carcinogenesis. 2012 Dec;33(12):2593-600. doi: 10.1093/carcin/bgs298. Epub 2012 Oct 1. PMID: 23027628 [PubMed - indexed for MEDLINE] Free Article
Zhu J, Li X, Kong X, Moran MS, Su P, Haffty BG, Yang Q. Testin is a tumor suppressor and prognostic marker in breast cancer. Cancer Sci. 2012 Dec;103(12):2092-101. doi: 10.1111/cas.12020. Epub 2012 Oct 22. PMID: 22957844 [PubMed - indexed for MEDLINE] Free Article
Axelrod DE, Shah K, Yang Q, Haffty BG. Prognosis for Survival of Young Women with Breast Cancer by Quantitative p53 Immunohistochemistry. Cancer Clin Oncol. 2012;1(1):52-64. PMID: 26322145
Neboori HJ, Haffty BG, Wu H et. al.; Low p53 Binding Protein 1 (53BP1) Expression is Associated with Increased Local Recurrence in Breast Cancer Patients Treated with Breast Conserving Surgery and Radiation Therapy (BCS+RT); International Journal of Radiation Oncology, Biology, Physics. PMID:22520477; Published August, 2012
Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M, Yan J, Hua Y, Tiede BJ, Lu X, Haffty BG, Pantel K, Massagué J, Kang Y. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell. 2011 Dec 13;20(6):701-14. doi: 10.1016/j.ccr.2011.11.002. Epub 2011 Dec 1. PMID: 22137794
Taunk NK, Goyal S, Wu H, Moran MS, Chen S, Haffty BG. DEAD box 1 (DDX1) expression predicts for local control and overall survival in early stage, node-negative breast cancer. Cancer. 2012 Feb 15;118(4):888-98. doi: 10.1002/cncr.26352. Epub 2011 Jul 14. PMID: 21761397
Jiang J, Yang ES, Jiang G, Nowsheen S, Wang H, Wang T, Wang Y, Billheimer D, Chakravarthy AB, Brown M, Haffty B, Xia F. p53-dependent BRCA1 nuclear export controls cellular susceptibility to DNA damage. Cancer Res. 2011 Aug 15;71(16):5546-57. doi: 10.1158/0008-5472.CAN-10-3423. Epub 2011 Jul 8. PMID: 21742769
Taunk NK, Haffty BG, Goyal S. Radiation recall 5 years after whole-breast irradiation for early-stage breast cancer secondary to initiation of rosuvastatin and amlodipine. J Clin Oncol. 2011 Aug 1;29(22):e661-3. doi: 10.1200/JCO.2011.35.7202. No abstract available.
Taunk NK, Haffty BG, Chen S, Khan AJ, Nelson C, Pierce D, Goyal S. Comparison of radiation-induced fatigue across 3 different radiotherapeutic methods for early stage breast cancer. Cancer. 2011 Sep 15;117(18):4116-24. doi: 10.1002/cncr.26013.
Taunk NK, Goyal S, Moran MS, Yang Q, Parikh R, Haffty BG. Prognostic significance of IGF-1R expression in patients treated with breast-conserving surgery and radiation therapy. Radiother Oncol. 2010 Aug;96(2):204-8. doi: 10.1016/j.radonc.2010.03.009.
Jiang L, Ma T, Moran MS, Kong X, Li X, Haffty BG, Yang Q. Mammographic features are associated with clinicopathological characteristics in invasive breast cancer. Anticancer Res. 2011 Jun;31(6):2327-34. PMID: 21737659
Zhang N, Li X, Tao K, Jiang L, Ma T, Yan S, Yuan C, Moran MS, Liang F, Haffty BG, Yang Q. BCL-2 (-938C > A) polymorphism is associated with breast cancer susceptibility. BMC Med Genet. 2011 Apr 1;12:48. doi: 10.1186/1471-2350-12-48. PMID: 21457555
Khan AJ, Wall B, Ahlawat S, Green C, Schiff D, Mehnert JM, Goydos JS, Chen S, Haffty BG. Riluzole enhances ionizing radiation-induced cytotoxicity in human melanoma cells that ectopically express metabotropic glutamate receptor 1 in vitro and in vivo. Clin Cancer Res. 2011 Apr 1;17(7):1807-14. doi: 10.1158/1078-0432.CCR-10-1276. Epub 2011 Feb 15. PMID: 21325066
Moran MS, Yang Q, Goyal S, Harris L, Chung G, Haffty BG. Evaluation of vascular endothelial growth factor as a prognostic marker for local relapse in early-stage breast cancer patients treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1236-43. doi: 10.1016/j.ijrobp.2010.07.031. Epub 2010 Nov 17. PMID: 21093162 [PubMed - indexed for MEDLINE]
Haffty BG, Goyal S, Kulkarni D, Green C, Vazquez A, Schiff D, Moran MS, Yang Q, Ganesan S, Hirsfield KM. Evaluation of single nucleotide polymorphisms (SNPs) in the p53 binding protein 1 (TP53BP1) gene in breast cancer patients treated with breast-conserving surgery and whole-breast irradiation (BCS + RT). Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):385-91. doi: 10.1016/j.ijrobp.2010.02.005. Epub 2010 Jun 18. PMID: 20646866
Patel AN, Goyal S, Wu H, Schiff D, Moran MS, Haffty BG. Mediator of DNA damage checkpoint protein 1 (MDC1) expression as a prognostic marker for nodal recurrence in early-stage breast cancer patients treated with breast-conserving surgery and radiation therapy. Breast Cancer Res Treat. 2011 Apr;126(3):601-7. doi: 10.1007/s10549-010-0960-6. Epub 2010 Jun 3. PMID: 20521098
Bouwman P, Aly A, Escandell JM, Pieterse M, Bartkova J, van der Gulden H, Hiddingh S, Thanasoula M, Kulkarni A, Yang Q, Haffty BG, Tommiska J, Blomqvist C, Drapkin R, Adams DJ, Nevanlinna H, Bartek J, Tarsounas M, Ganesan S, Jonkers J. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol. 2010 Jun;17(6):688-95. doi: 10.1038/nsmb.1831. Epub 2010 May 9. PMID: 20453858
Moran MS, Yang Q, Haffty BG. The Yale University experience of early-stage invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) treated with breast conservation treatment (BCT): analysis of clinical-pathologic features, long-term outcomes, and molecular expression of COX-2, Bcl-2, and p53 as a function of histology. Breast J. 2009 Nov-Dec;15(6):571-8. doi: 10.1111/j.1524-4741.2009.00833.x. PMID: 19995377
Hu G, Chong RA, Yang Q, Wei Y, Blanco MA, Li F, Reiss M, Au JL, Haffty BG, Kang Y. MTDH activation by 8q22 genomic gain promotes chemoresistance and metastasis of poor-prognosis breast cancer. Cancer Cell. 2009 Jan 6;15(1):9-20. doi: 10.1016/j.ccr.2008.11.013. PMID: 19111877
Rewari A, Lu H, Parikh R, Yang Q, Shen Z, Haffty BG. BCCIP as a prognostic marker for radiotherapy of laryngeal cancer. Radiother Oncol. 2009 Feb;90(2):183-8. doi: 10.1016/j.radonc.2008.10.020. Epub 2008 Nov 27. PMID: 19046788
Moran MS, Yang Q, Harris LN, Jones B, Tuck DP, Haffty BG. Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast cancer. Cancer. 2008 Nov 1;113(9):2565-74. doi: 10.1002/cncr.23881. PMID: 18816610
Parikh RR, Housman D, Yang Q, Toppmeyer D, Wilson LD, Haffty BG. Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer. Int J Radiat Oncol Biol Phys. 2008 Nov 15;72(4):1056-63. doi: 10.1016/j.ijrobp.2008.02.066. PMID: 18676094
Yang Q, Moran MS, Haffty BG. Bcl-2 expression predicts local relapse for early-stage breast cancer receiving conserving surgery and radiotherapy. Breast Cancer Res Treat. 2009 May;115(2):343-8. doi: 10.1007/s10549-008-0068-4. Epub 2008 May 31. PMID: 18516673
Parikh RR, Yang Q, Higgins SA, Haffty BG. Outcomes in young women with breast cancer of triple-negative phenotype: the prognostic significance of CK19 expression. Int J Radiat Oncol Biol Phys. 2008 Jan 1;70(1):35-42. Epub 2007 Sep 12. PMID: 17855007